



FRIDAY 6 SEPTEMBER 2019				
07:15	Industry Symposia 07:15 - 08:45			
09:00	Plenary Scientific Session 1 - CGRP and CGRP mAbs 09:00 - 10:00 09:00-09:15 - Review lecture on CGRP role in migraine: evidence from clinical and preclinical studies 09:15-09:30 - CGRP-mAbs overall efficacy, ability to completely eliminate migraine in some patients but make no difference for others, safety profile, and lack of CNS adverse events. 09:30-09:45 - Chronic episodic migraine, vs. chronic migraine: lessons learned from CGRP-mAbs 09:45-10:00 - Discussion			
10:00	Plenary Scientific Session 2 - Why is it that almost all drugs and devices developed for the treatment of migraine succeed whereas almost all drugs and devices developed for pain fail? 10:00 - 11:00 10:00-10:15 - Review clinical trials in pain and migraine in the past 20 years. 10:15-10:30 - Role of primary and secondary outcome measures in defining success and failure. 10:30-10:45 - Do we need more relevant clinical trial designs & endpoints for acute and prophylactic migraine treatment? 10:45-11:00 - Discussion			
11:00	Break and Poster Walk I 11:00 - 12:00			
12:00	IHS Advisory Council 12:00-12:45			
12:45	Break and pick up lunch boxes 12:45 - 13:00			
13:00	Lunch Session 1 - Inflammation and migraine 13:00-14:00 13:00-13:10 - Clinical evidence for inflammation role in migraine. 13:10-13:15 - Discussion 13:15-13:25 - The inflammosome story 13:25-13:30 - Discussion 13:30-13:40 - Imaging inflammation in migraine patients 13:40-13:45 - Discussion 13:45-13:55 - Imaging inflammation in animal models of migraine. 13:55-14:00 - Discussion	Lunch Session 2 - The interplay between genetic and the environmental in pediatric headache 13:00 - 14:00 13:00-13:15 - Role of genetic in migraine onset in childhood 13:15-13:30 - Role of environment in migraine onset in childhood 13:30-13:45 - Does it matter? 13:45-14:00 - Discussion	Lunch Session 3 - Is there a role for endocannabinoids in the treatment of migraine or cluster headache? 13:00-14:00 13:00-13:20 - Cannabinoids: hopes or bluster and potential risks 13:20-13:40 - Endocannabinoids and marijuana: examining the basic science and the therapeutic benefit. 13:40-14:00 - Discussion	One Topic Two Views 1 - Are functional or structural brain changes cause or result of migraine and can they predict progression of disease? 13:00-14:00 13:00-13:05 - Chairman Introduction 13:05-13:20 - Structural brain changes are real and permanent 13:20-13:35 - Brain state vs. Brain trait 13:35-13:50 - fMRI studies cannot predict progression of disease years before it occurs 13:50-14:00 - Discussion
14:00	One Topic Two Views 2 - Novel views on post-traumatic headache 14:00-15:00 14:00-14:05 - Chairman Introduction Chairman questions: How can post-traumatic headache trigger chronic migraine if migraine is a genetic disorder? 14:05-14:25 - Post-traumatic headache is a primary headache with a head trauma as a trigger. 14:25-14:45 - Psychogenic vs. neurogenic origin of post-traumatic headache. 14:45-15:00 - Discussion	One Topic Two Views 3 - Behavioral animal models of migraine: are we wasting our time? 14:00-15:00 14:00-14:05 - Chairman Introduction 14:05-14:25 - Behavioral animal model are not good enough to predict what will happen in the clinic 14:25-14:45 - Behavioral animal model are good enough to predict what will happen in the clinic 14:45-15:00 - Discussion	IHS fellowships 1 14:00-15:00	Exhibition Open 09:00 - 17:30
15:00	Plenary Scientific Session 3 - IASP/IHS: Crosstalk between social interactions and pain behavior 15:00 - 16:00 15:00-15:15 - Headache in social context 15:15-15:30 - Chronic pain in social content 15:30-15:45 - Environmental factors coding pain sensitivity: The epigenetic era 15:45-16:00 - Discussion			
16:00	Break 16:00 - 16:15			
16:15	One Topic Two Views 4 - Is aura a brain-damaging event? 16:15-17:15 16:15-16:20 - Chairman introduction 16:20-16:35 - Aura/CSD effect on vasculature and brain parenchyma 16:35-16:50 - Aura and CSD are events that damage the brain and its vasculature - possible explanation for the increase risk of stroke. 16:50-17:05 - Aura and CSD are events that do not damage the brain or its vasculature. 17:05-17:15 - Discussion	One Topic Two Views 5 - Is cardiovascular risk a marketing gimmick or a real factor in treatment options? 16:15-17:15 16:15-16:20 - Chairman Introduction 16:20-16:40 - Cardiovascular risk in migraine and the implications for treatment options 16:40-17:00 - Cardiovascular risk does not commonly prevent the use of triptans 17:00-17:15 - Discussion	One Topic Two Views 6 - CGRP mAbs and CGRP receptor antagonists site of action 16:15 - 17:15 16:15-16:20 - Chairman Introduction 16:20-16:40 - The central action of CGRP-mAb is the main reason for its efficacy 16:40-17:00 - The peripheral action of CGRP-mAb is the main reason for its efficacy 17:00-17:15 - Discussion	
17:15	Industry Symposia 17:15 - 18:45			
18:45				